Treatment and prevention of venous thromboembolic events: Present and future antithrombotic agents;Maladie thrombo-embolique veineuse: Médicaments antithrombotiques d'aujourd'hui et de demain

Bulletin de l'Academie Nationale de Medecine

Volumn 187, Issue 1, 2003, Pages 85-97

  Drouet, Ludovic ^a   Bégué, M Pierre ^b   Godeau, M Pierre ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b NONE

Author keywords

Antagonists and inhibitors; Antithrombins; Embolism and thrombosis; Factor Xa; Polysaccharides; Venous thrombosis

Indexed keywords

AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; DRUG DERIVATIVE; FACTOR IIA; FIBRINOLYTIC AGENT; FONDAPARINUX; GLYCINE; MELAGATRAN; POLYSACCHARIDE; PRODRUG; PROTHROMBIN; THROMBIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY THROMBOSIS; DRUG ANTAGONISM; HUMAN; ORAL DRUG ADMINISTRATION; ORTHOPEDICS; RESEARCH; REVIEW; SYNTHESIS; THROMBOEMBOLISM; TIME; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; AZETIDINES; BENZYLAMINES; CLINICAL TRIALS; CORONARY THROMBOSIS; FACTOR XA; FIBRINOLYTIC AGENTS; GLYCINE; HIRUDIN THERAPY; HUMANS; ORTHOPEDICS; POLYSACCHARIDES; PRODRUGS; PROTHROMBIN; RESEARCH; THROMBIN; THROMBOEMBOLISM; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0642305979     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)34082-8     Document Type: Article

References (12)

1. TURPIE A.G., GALLUS A.S., HOEK J.A. - A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med, 2001, 344, 619-625.
2. BAUER K.A., ERIKSSON B.I., LASSEN M.R., TURPIE A.G. - Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N.Engl.J.Med., 2001, 345, 1305-1310.
3. ERIKSSON B.I., BAUER K.A., LASSEN M.R., TURPIE A.G. - Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N.Engl.J.Med., 2001,345, 1298-1304.
4. LASSEN M.R., BAUER K.A., ERIKSSON D.I., TURPIE A.G. - Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hipreplacement surgery : a randomised double-blind comparison. Lancet, 2002, 359, 1715-1720.
5. TURPIE A.G., BAUER K.A., ERIKSSON B.I., LASSEN M.R. - Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery : a randomised double-blind trial. Lancet, 2002, 359, 1721-1726.
6. TURPIE A.G., BAUER K.A., ERIKSSON B.I., LASSEN M.R. - Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery : A Meta-analysis of 4 Randomized Double-blind Studies. Arch.Intern.Med, 2002, 162, 1833-1840.
7. BARRÉ J., SAMAMA C.M., MISMETTI P. - La thrombose asymptomatique en orthopédie : outil méthodologique ou critère intermédiaire ? Sang, Thrombose, Vaisseaux, 2002, 14, 341-346.
8. GALLUS A.S., COGHLAN D.W. - Heparin pentasaccharide. Curr.Opin.Hematol., 2002, 9, 422-429.
9. BULLER H.R. - Fondaparinux and synthetic pentasaccharides in clinical practice. Oral presentation - 48th Annual SSC Meeting, Boston, MA, July 18-20, 2002.
10. ERIKSSON B.I., ARFWIDSSON A.C., FRISON L., ERIKSSON U.G., BYLOCK A., KALEBO P., FAGER G., GUSTAFSSON D. - A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement : METHRO I. Melagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost, 2002, 87, 231-237.
11. ERIKSSON B.I., BERGQVIST D., KALEBO P., DAHL O.E., LINDBRATT S., BYLOCK A., FRISON L., ERIKSSON U.G., WELIN L., GUSTAFSSON D. - Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement : the METHRO II randomised trial. Lancet, 2002, 360, 1441-1447.
12. ERIKSSON B.I., WAHLANDER K., GUSTAFSSON D., WELIN L., FRISON L., SCHULMAN S. - Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95), compared with standard therapy for the treatment of acute deep vein thrombosis. XVIII ISTH Thromb Haemost, 2001, 86 (suppl), Abstract OC2348-M.